BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cornell RF, Costa LJ. The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma. Biol Blood Marrow Transplant 2019;25:e73-5. [PMID: 30448457 DOI: 10.1016/j.bbmt.2018.11.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Holstein SA, Suman VJ, Owzar K, Santo K, Benson DM Jr, Shea TC, Martin T, Silverman M, Isola L, Vij R, Cheson BD, Linker C, Anderson KC, Richardson PG, McCarthy PL. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biol Blood Marrow Transplant 2020;26:1414-24. [PMID: 32325171 DOI: 10.1016/j.bbmt.2020.03.028] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Uckun FM, Qazi S, Demirer T, Champlin RE. Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. EBioMedicine 2019;39:612-20. [PMID: 30545798 DOI: 10.1016/j.ebiom.2018.12.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
3 Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 2020;26:e7-e15. [PMID: 31526843 DOI: 10.1016/j.bbmt.2019.09.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]